New Shingles Vaccine: CUIMC Experts Discuss What It Means for Patients

A new vaccine could help millions of Americans over 50 avoid shingles, a painful rash that occurs in one in three adults who have had a childhood case of the chickenpox.

Shingles is caused by reactivation of the virus that causes chickenpox, varicella zoster virus (VZV). After infection, VZV lies dormant, often for years, in sensory nerves. An estimated 99.5 percent of people over 40 harbor latent VZV. But as the immune system weakens due to age, disease, or medications, the virus can come roaring back to life as shingles. More than half of all adults age 85 and older have experienced shingles at least once.

The new vaccine, Shingrix, is about 97 percent effective in preventing shingles in adults age 50 to 70 or older. Zostavax, the original shingles vaccine, is just over 50 percent effective and does not work as well in people age 70 and older.

The CDC’s immunization advisory committee issued a statement last month recommending Shingrix over Zostavax for adults over 50, including adults previously vaccinated with Zostavax.

The main reason for the new vaccine’s improved efficacy lies in the way it stimulates the immune system, says Anne Gershon, MD, a pediatric infectious disease specialist at Columbia University Irving Medical Center (CUIMC) who is an expert on VZV.

Shingrix delivers an antigen—the part of the virus that stimulates an immune response—and an adjuvant that amplifies this response. In contrast, Zostavax uses a live, but weakened, virus as its antigen, which multiplies in a vaccinated person to induce an immune response. It does not contain an adjuvant.

“Live, weakened-virus vaccines may be less capable of inducing a strong immune response in people with an immune system that has already been impaired by aging,” Dr. Gershon says. “The adjuvant approach is so much more effective that it could eventually make some live attenuated virus vaccines obsolete.” She also notes that, unlike Zostavax, which contains live virus, Shingrix does not pose a threat to those who are immunocompromised.

The new vaccine is also more effective in reducing the risk of developing one of the most common complications of shingles, postherpetic neuralgia. In most shingles cases, the rash disappears after a few weeks, but about 20 percent of patients later develop severe nerve pain around the skin where the rash was present. The pain can last for months or, in rare cases, years. Shingles can cause other serious complications, such as eye infections, brain involvement, and intestinal ulcers.

“There’s no good treatment for postherpetic neuralgia and other complications, so we rely on vaccines to cut down the risk of having a shingles outbreak in the first place,” Dr. Gershon says.

But efficacy is not the only consideration when deciding whether to be vaccinated. Zostavax is given in one dose, although a booster dose may eventually be needed. Shingrix requires two doses, given two to six months apart. Currently, it is unknown whether a booster shot will be needed with Shingrix. “The two-dose schedule could be a deterrent to many older people,” says Evelyn Granieri, MD, a geriatric medicine expert at CUIMC.

Cost may be another consideration. The new vaccine is slightly more expensive than the old vaccine. And while Shingrix, like Zostavax, is expected to be covered under Medicare Part D, not everyone with Medicare has a Part D plan. “This could be a deal breaker for seniors who are living on a fixed income and have to prioritize their health care expenditures,” says Dr. Granieri.

“But for those who are already paying out of pocket, the improvement in effectiveness may be worth the slight increase in cost,” says Dr. Gershon.


Anne Gershon, MD, is professor of pediatrics at Columbia.

Evelyn Granieri, MD, is professor of medicine at Columbia in geriatric medicine and aging.